Bioengineered blood vessel for Coronary Bypass Sustains 18-Month Patency — With a Full Year without Blood Thinners
Nature Communications study reports an off-the-shelf bioengineered coronary conduit that remained patent for 18 months after anticoagulation was withdrawn, advancing a ready-to-use alternative for the hundreds of thousands of patients who undergo coronary bypass each year ST. PAUL, Minn., Aug. 21, 2026 (GLOBE NEWSWIRE) — Vascudyne, Inc. today announced the publication in Nature Communications of […]
Financial Post
Published by CurrentWire · First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from Financial Post.
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
Financial Post (financialpost.com), a Tier B publisher, filed this report on . CurrentWire published this page 8 minutes later, on .
Signal breakdown
CurrentWire ranked this story 51.1 of 100 in the snapshot this page was rendered from.
- Freshness
- 30.1 of 35
- Source authority
- 7 of 20
- Coverage breadth
- 4 of 20
- Geographic relevance
- 3.5 of 10
- Story prominence
- 6.5 of 10
- Velocity
- 0 of 5
Strongest signal: freshness, 30.1 of 35. How each signal is calculated.
Filed under Business · International · Press release. Topics extracted from this report, with other live CurrentWire stories mentioning each: Coronary Bypass Sustains (none), Full Year (none), Blood Thinners (none).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.